inotuzumab ozogamicin
Drug Details
- Generic Name
- inotuzumab ozogamicin
- Brand Names
- Besponsa
- Application Number
- BLA761040
- Sponsor
- Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
- NDC Codes
- 1
- Dosage Forms
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Routes
- INTRAVENOUS
- Active Ingredients
- INOTUZUMAB OZOGAMICIN
Indications and Usage
1. INDICATIONS AND USAGE BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older . BESPONSA is a CD22-directed antibody and cytotoxic drug conjugate indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older. ( 1 )